PUMA BIOTECHNOLOGY INC (PBYI)

Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 192 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Company Info

PUMA BIOTECHNOLOGY INC

10880 Wilshire Blvd., Suite 2150

Los Angeles CALIFORNIA 90024

P: 14242486500

CEO: Alan H. Auerbach

Employees: 192

Website: https://www.pumabiotechnology.com/